נוביטרופן 5 מג טבליות
cts chemical industries ltd, israel - oxybutynin hydrochloride - טבליה - oxybutynin hydrochloride 5 mg - oxybutynin - oxybutynin - relief of symptoms associated with voiding in patients with uninhibited neurogenic and reflux neurogenic bladder.
איטרנול
rafa laboratories ltd - itraconazole - קפסולות - itraconazole 100 mg - itraconazole - itraconazole - blastomycosis (pulmonary and extrapulmonary). histoplasmosis. onchomycosis caused by dermatophytes and/or yeast. dermatomycoses. vulvovaginal candidosis. oral candidosis. prevention of fungal infection during neutropenia in immunodeficient patients.
פלומיסט קואדריוואלנט
astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.
רמיקד
j-c health care ltd - infliximab - אבקה להכנת תרכיז לאינפוזיה - infliximab 100.0 mg/vial - infliximab - infliximab - - adult :crohn's disease: treatment of severe active crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. treatment of fistulising crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -paediatric crohn's disease: remicade is indicated for: treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy -ankylosing spondylitis: remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther
אתופן 400
taro pharmaceutical industries ltd - etodolac - טבליה - etodolac 400 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthritis and rheumatoid arthritis. for the management of pain.
אתופן 200
taro pharmaceutical industries ltd - etodolac - קפסולות - etodolac 200 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthritis and rheumatoid arthritis. for the management of pain.
אתופן 300
taro pharmaceutical industries ltd - etodolac - קפסולות - etodolac 300 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthritis and rheumatoid arthritis. for the management of pain.
אתופן 500
taro pharmaceutical industries ltd - etodolac - טבליה - etodolac 500 mg - etodolac - etodolac - for the managament of signs and symptoms of osteoarthritis and rheumatoid arthritis.for the management of pain.
אתופן xl 600
taro pharmaceutical industries ltd - etodolac - טבליות עם שחרור נרחב - etodolac 600 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthritis and rheumatoid arthritis.
אתופן xl 400
taro pharmaceutical industries ltd - etodolac - טבליות עם שחרור נרחב - etodolac 400 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthrities and rheumatoid arthritis.